Gossamer Bio Awaits Pivotal Seralutinib Data for Pulmonary Arterial Hypertension This Month
核心洞察
Gossamer Bio expects to announce topline results from its Phase 3 PROSERA trial evaluating seralutinib for pulmonary arterial hypertension (搜索) (PAH) before the end of February 2026.
The fully enrolled study includes 390 WHO Functional Class II and III PAH patients, with the primary endpoint measuring change in six-minute walk distance after 24 weeks of treatment.
Seralutinib is an inhaled small molecule inhibitor targeting PDGFR (搜索), CSF1R (搜索), and c-KIT (搜索) receptors, designed to address the underlying mechanisms of PAH through a dry powder inhaler.
Gossamer Bio Inc. (GOSS) stands at a critical inflection point as the company prepares to announce topline results from its Phase 3 PROSERA trial evaluating seralutinib for pulmonary arterial hypertension (搜索) (PAH) before the end of February 2026. The data readout represents a primary value driver for the company's stock and a fundamental prerequisite for potential regulatory submission.
PROSERA Trial Design and Patient Population
The PROSERA study is a double-blind, placebo-controlled, global registrational clinical trial that has fully enrolled 390 WHO Functional Class II and III PAH patients. Patient recruitment was completed in June 2025, keeping the company on track for its February timeline. The trial evaluates seralutinib on top of background PAH therapy, with the primary endpoint measuring change in six-minute walk distance (6MWD) from baseline compared to placebo at week 24.
Key secondary endpoints include time to clinical worsening compared to placebo up to week 48, along with additional secondary and exploratory endpoints focused on safety and tolerability evaluation.
Seralutinib's Mechanism and Delivery
Seralutinib is an investigational, inhaled, small molecule inhibitor targeting platelet-derived growth factor receptor (PDGFR (搜索)), colony-stimulating factor 1 receptor (CSF1R (搜索)), and mast/stem cell growth factor receptor kit (c-KIT (搜索)). The drug is designed to target the mechanisms underlying pulmonary arterial hypertension (搜索) and is delivered directly to the site of disease via a dry powder inhaler.
Addressing Significant Unmet Medical Need
Pulmonary arterial hypertension (搜索) is characterized by abnormally high blood pressure in the arteries carrying deoxygenated blood from the right side of the heart to the lungs. The condition is caused by abnormal cell growth in and around these vessels, leading to structural and functional changes known as vascular remodeling. In the United States, an estimated 30,000 to 50,000 people live with PAH, with a five-year survival rate of approximately 57%.
Despite several approved vasodilators and diuretics for PAH management, significant unmet clinical needs persist. Current therapies often involve complex administration methods, including continuous intravenous infusions, which carry risks of infection, require bulky external pumps, and are associated with substantial side effects. While these treatments can alleviate symptoms, they do not halt disease progression.
Expanding Pipeline with SERANATA Trial
Beyond the PAH indication, Gossamer Bio has initiated the Phase 3 SERANATA trial for pulmonary hypertension associated with interstitial lung disease (搜索) (PH-ILD). The 24-week, randomized, double-blind, placebo-controlled global clinical trial is designed to enroll approximately 480 PH-ILD patients, with the first clinical site activated in November 2025.
The SERANATA study shares the same primary endpoint as PROSERA - change in six-minute walk distance from baseline compared to placebo at week 24. Key secondary endpoints include time to clinical worsening and change from baseline in forced vital capacity (FVC).
PH-ILD is a rare, progressive, and often fatal condition affecting small airways in the lungs, including forms such as pulmonary hypertension linked to idiopathic pulmonary fibrosis (搜索) (PH-IPF) and connective tissue disease-associated interstitial lung disease (PH-CTD-ILD). In the United States, an estimated 60,000 to over 100,000 people currently live with PH-ILD, with a three-year survival rate of approximately 40%.
Strategic Partnership and Market Activity
Seralutinib is being developed through a global collaboration with the Chiesi Group (搜索), established in 2024, which would oversee commercialization following a positive outcome. In the lead-up to the data release, trading in Gossamer Bio shares has shown increased volatility, with market observers noting heightened activity in put options.
The stock has garnered significant institutional attention following its addition to two major indices in late January: the NASDAQ Biotechnology Index and the S&P Biotechnology Select Industry Index. Such inclusions typically trigger automatic buying from index-tracking exchange-traded funds and other institutional portfolios.
Financial Position and Strategic Expansion
As of September 30, 2025, Gossamer Bio held cash, cash equivalents, and marketable securities of $180.2 million, sufficient to fund operating and capital expenditures into 2027. This financial runway supports not only the PAH program but also exploration of seralutinib in additional disease areas.
In September 2025, the company entered into a strategic option agreement to acquire Respira Therapeutics (搜索) Inc., expanding its pulmonary hypertension franchise. Respira's lead product candidate is an inhaled formulation of vardenafil in development for as-needed use in pulmonary hypertension, including PAH and PH-ILD, for which there are no currently approved PRN products. If Gossamer proceeds with the acquisition, it will pay by issuing 1.5 million shares of common stock, representing less than 1% of total shares outstanding.
Gossamer shares have traded in a range of $0.76 to $3.87 over the past year, closing at $2.29 on February 13, 2026, down 1.29%.